GPhA Statement on the Introduction of the Bipartisan Biogenerics Consensus Bill: 'Promoting Innovation and Access to Life-Saving Med... ( Hails Legislation as Pro-Patient and ...)

HOME >> BIOLOGY >> TECHNOLOGY

GPhA Statement on the Introduction of the Bipartisan Biogenerics Consensus Bill: 'Promoting Innovation and Access to Life-Saving Medicine Act'

Date:3/11/2009

Hails Legislation as Pro-Patient and Pro-Pharmaceutical Innovation

ARLINGTON, Va., March 11 /PRNewswire/ -- The Generic Pharmaceutical Association (GPhA) released the following statement today from GPhA President and CEO Kathleen Jaeger regarding the introduction of H.R. 1427, the Bipartisan Biogenerics Consensus Bill: "Promoting Innovation and Access to Life-Saving Medicine Act."

"For the countless patients who are unable to afford the biopharmaceutical medicines they desperately need, today's bipartisan introduction of the 'Promoting Access to Life-Saving Medicine Act' provides great hope that they will soon be able to obtain high quality care at more affordable costs. We applaud Chairman Henry Waxman (D-CA) and Rep. Nathan Deal (R-GA), Rep. Frank Pallone (D-NJ) and Rep. Jo Ann Emerson (R-MO) for working together to introduce this consensus bill that achieves the balance of fostering pharmaceutical innovation while also making affordable medicines available to consumers. And we look forward to the bipartisan introduction of a companion bill in the Senate in the near future.

"As our nation acts to strengthen our health care system, our priority must be to reduce costs while increasing access to quality care. Studies continue to show that creating a workable biogenerics approval pathway will not only bring life-saving medicines to patients in need, it will also save our health care system billions of dollars.

"That's why consumer, business and labor organizations, AARP and many of our nation's governors support legislation that brings biogeneric medicines to consumers sooner rather than later through timely resolution of patent disputes and market exclusivity provisions consistent with the Hatch-Waxman model. Over the past two years, members of Congress have learned a great deal about biogenerics. They've heard from the FDA that the science exists to approve safe, effective and af
'/>"/>

0

GOOD

Page: 1 2
Related biology technology :

1. CV Therapeutics Statement on Unsolicited Proposal From Astellas
2. Sinovac Releases Statement on Healive Vaccine Suspension
3. Helix BioPharma Files Form 20-F Registration Statement With the U.S. Securities and Exchange Commission
4. Extraordinary General Meetings Statement - XTL Notifies NASDAQ of Compliance with Marketplace Rule 4350(d)(2)
5. Resverlogix Issues a Management Statement
6. A Statement From Larry Corey, MD, of the HIV Vaccine Trials Network Regarding the New HIV Infection Statistics Released Today by the Centers for Disease Control
7. Jazz Pharmaceuticals Files Form S-3 Registration Statements
8. Catalyst Pharmaceutical Partners, Inc. Files Form S-3 Shelf Registration Statement
9. Statement from Lighthouse International About the Study on Gene Therapy Concerning Lebers Congenital Amaurosis
10. Occlutech Clarifies Statement Regarding Favourable Opinion Obtained From AIPPI With Regard to Patents Held by AGA Medical
11. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering

Post Your Comments:

GPhA Statement on the Introduction of the Bipartisan Biogenerics Consensus Bill: 'Promoting Innovation and Access to Life-Saving Med...( Hails Legislation as Pro-Patient and ...)